MT-ND6 and Parkinson disease: In the Parkinson’s disease model in vitro, 1-methyl-4-phenyl-pyridinium (MPP+)-injured SN4741 cells, salidroside pretreatment improved cellular viability, inhibited apoptosis, and restored the mitochondrial membrane potential and complex I activity via regulation of the mitochondrial myocyte enhancer factor 2D (MEF2D), NADH dehydrogenase 6 (ND6) pathway [65].